<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408989</url>
  </required_header>
  <id_info>
    <org_study_id>MB02-A-06-20</org_study_id>
    <nct_id>NCT04408989</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and USlicensed Avastin®.</brief_title>
  <official_title>A Randomized, Double-Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02-SP, MB02-DM (Bevacizumab Biosimilar Drugs)and US-licensed Avastin® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare&#xD;
      the PK, safety and immunogenicity profile of MB02-DM with MB02-SP and US-Avastin® in healthy&#xD;
      male subjects.&#xD;
&#xD;
      During the course of the study, the similarity in pharmacokinetics will be assessed by&#xD;
      sampling the levels of drug in the blood, and by comparing these levels among the different&#xD;
      administration arms. Safety, tolerability, and immunologic response to the administered drugs&#xD;
      will also be evaluated throughout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary PK parameter endpoints are Cmax and AUC0-∞ for bevacizumab. The secondary PK&#xD;
      endpoints will include all other PK parameters for bevacizumab, including tmax, t1/2, CL and&#xD;
      AUC(0-t).&#xD;
&#xD;
      The serum PK parameters of bevacizumab will be calculated using standard noncompartmental&#xD;
      methods. An analysis of covariance model will be used to analyse the log-transformed primary&#xD;
      PK parameters (AUC[0 ∞] and Cmax) and AUC(0-t). The model will include a fixed effect for&#xD;
      treatment and body weight as a covariate.&#xD;
&#xD;
      All other PK parameters will not be subject to inferential statistical analysis.&#xD;
&#xD;
      Estimates of geometric mean ratios together with the corresponding 90% confidence intervals&#xD;
      (CI) will be derived for the comparisons of the PK parameters as follows:&#xD;
&#xD;
        -  MB02-SP versus MB02-DM&#xD;
&#xD;
        -  MB02-SP versus US Avastin®&#xD;
&#xD;
        -  MB02-DM versus US Avastin® PK similarity will be achieved if the 90% CIs for the&#xD;
           biosimilar-to-reference ratios of PK endpoints (AUC[0-∞] and Cmax) fall within the&#xD;
           predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons;&#xD;
           MB02-SP versus MB02-DM; MB02-SP versus US Avastin®; and MB02-DM versus US Avastin®.&#xD;
&#xD;
      All AEs will be listed and summarised using descriptive methodology. All observed or&#xD;
      patient-reported AEs will be graded by the National Cancer Institute Common Terminology&#xD;
      Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be&#xD;
      presented by severity and by association with the study drugs as determined by the&#xD;
      Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory&#xD;
      Activities. All safety data will be listed and summarised as appropriate.&#xD;
&#xD;
      Immunogenicity data (overall ADA incidence and titters, and neutralising ADA results) will be&#xD;
      listed. A summary of the number and percent of subjects testing positive for ADA or&#xD;
      neutralising antibodies before the dose of MB02-SP, MB02-DM, or US Avastin® (Day -1) and at&#xD;
      scheduled post dose assessments will be presented by treatment arm. All safety data and&#xD;
      immunogenicity data summaries will be based on the safety analysis population. Select&#xD;
      analyses may be repeated for subsets with or without ADA and de novo ADA formation as&#xD;
      appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - (AUC[0-∞])</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Compare the pharmacokinetic (PK) profiles of the 3 arms (AUC[0-∞])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - (Cmax)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Compare the pharmacokinetic (PK) profiles of the 3 arms (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters (tmax)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Evaluation of all other PK parameters (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters (AUC[0 t])</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Evaluation of all other PK parameters (AUC[0 t])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters (CL)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Evaluation of all other PK parameters (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters (t1/2)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Evaluation of all other PK parameters (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1 - Day 78</time_frame>
    <description>Incidence of anti-bevacizumab antiboides (ADA), including neutralizing antibodies (Nab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Incidence of Treatment-related Adverse Events)</measure>
    <time_frame>Day 1 - Day 100</time_frame>
    <description>Incidence of Treatment-related Adverse Events using CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MB02-SP (Bevacizumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB02-DM (Bevacizumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US licenced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB02-SP</intervention_name>
    <description>Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>MB02-SP (Bevacizumab Biosimilar)</arm_group_label>
    <other_name>MB02-SP (Bevacizumab Biosimilar)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB02-DM</intervention_name>
    <description>Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>MB02-DM (Bevacizumab Biosimilar)</arm_group_label>
    <other_name>MB02-DM (Bevacizumab Biosimilar)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US licenced Avastin®</intervention_name>
    <description>Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion</description>
    <arm_group_label>US licenced Avastin®</arm_group_label>
    <other_name>Bevacizumab (US sourced)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males of any race, between 18 and 55 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening.&#xD;
&#xD;
          3. Total body weight between 50 and 95 kg, inclusive, at Screening.&#xD;
&#xD;
          4. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations (congenital non-haemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is&#xD;
             acceptable) at Screening or Check-in as assessed by the Investigator (or designee).&#xD;
&#xD;
          5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and&#xD;
             clinical chemistry within normal range at Screening and Check in as follows. A single&#xD;
             repeat test will be allowed at each timepoint.&#xD;
&#xD;
               -  Absolute neutrophil count ≥1.5 × 109 L&#xD;
&#xD;
               -  Platelet count ≥100 × 109 L&#xD;
&#xD;
               -  Haemoglobin &gt;10 g/dl&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) ≤1.5 × ULN&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 × ULN (&lt;51.30 µmol/L in subjects with Gilbert's syndrome)&#xD;
&#xD;
               -  Blood urea nitrogen ≤1.5 × ULN&#xD;
&#xD;
               -  Creatinine &lt;132.63 µmol/L&#xD;
&#xD;
               -  Serum albumin: &gt;35 g/L&#xD;
&#xD;
               -  Low density lipoprotein cholesterol ≤ 4.9 mmol/L&#xD;
&#xD;
               -  High density lipoprotein cholesterol ≥ 0.85 mmol/L&#xD;
&#xD;
               -  Creatine kinase (CK) &lt;2 × ULN&#xD;
&#xD;
               -  International normalised ratio (INR) 0.8 to 1.3&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt;2+&#xD;
&#xD;
          6. Systolic blood pressure ≥90 mmHg and &lt;140 mmHg and diastolic blood pressure ≥50 mmHg&#xD;
             and &lt;90 mmHg at Screening and Check in.&#xD;
&#xD;
          7. Subjects agree to use contraception.&#xD;
&#xD;
          8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions. Subjects must have signed an informed consent before any&#xD;
             study-related procedure or evaluation is performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator (or designee).&#xD;
&#xD;
          3. Any current or recent history of active infections, including localised infections&#xD;
             (Within 2 months prior Screening Visit for any serious infection which requires&#xD;
             hospitalization or intravenous anti-infective, and within 14 days prior Screening&#xD;
             Visit for any active infection which requires oral treatment).&#xD;
&#xD;
          4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence&#xD;
             within 30 days of dosing, or within 30 days of the last study visit.&#xD;
&#xD;
          5. Presence of a nonhealing wound or fracture.&#xD;
&#xD;
          6. Known history of clinically significant essential hypertension, orthostatic&#xD;
             hypotension, fainting spells or blackouts for any reason, cardiac failure or history&#xD;
             of thromboembolic conditions.&#xD;
&#xD;
          7. Medically significant dental disease or dental neglect, with signs and/or symptoms of&#xD;
             local or systemic infection that would likely require a dental procedure during the&#xD;
             course of the study.&#xD;
&#xD;
          8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to&#xD;
             Check-in, and/or positive alcohol breath test and/or urinary drug test screen&#xD;
             (confirmed by repeat) at Screening or Check in.&#xD;
&#xD;
          9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden&#xD;
             deficiency.&#xD;
&#xD;
         10. History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids&#xD;
             and/or haemoptysis.&#xD;
&#xD;
         11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel&#xD;
             disease, diverticular disease, or any fistulae.&#xD;
&#xD;
         12. Alcohol consumption of &gt;24 units per week. One unit of alcohol equals ½ pint (285 mL)&#xD;
             of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.&#xD;
&#xD;
         13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results&#xD;
             are compatible with prior immunisation and not infection may be included at the&#xD;
             discretion of the Investigator.&#xD;
&#xD;
         14. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of&#xD;
             the investigational drug used in the study.&#xD;
&#xD;
         15. Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
         16. Use or intend use of any prescription medications/ nonprescription products known to&#xD;
             alter drug absorption, metabolism, or elimination processes, including St. John's&#xD;
             wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator&#xD;
             or designee.&#xD;
&#xD;
         17. Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         18. Have received a live or attenuated vaccine from 3 months prior to Screening or have&#xD;
             the intention to receive a vaccine during the study.&#xD;
&#xD;
         19. Intend to travel to a region where a vaccination will be required due to endemic&#xD;
             disease within 3 months of dosing.&#xD;
&#xD;
         20. Previous treatment with an anti VEGF antibody or any other protein or antibody&#xD;
             targeting the VEGF receptor.&#xD;
&#xD;
         21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or&#xD;
             positive cotinine test upon Screening or Check-in.&#xD;
&#xD;
         22. Receipt of blood products within 60 days prior to Check-in.&#xD;
&#xD;
         23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to&#xD;
             Screening, or platelets from 42 days prior to Screening.&#xD;
&#xD;
         24. Poor peripheral venous access.&#xD;
&#xD;
         25. History of abnormal peripheral sensation including paraesthesia and/or numbness in&#xD;
             arms and/or legs.&#xD;
&#xD;
         26. Have previously completed or withdrawn from this study or any other study&#xD;
             investigating bevacizumab, and/or have previously received bevacizumab.&#xD;
&#xD;
         27. Subjects who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
&#xD;
         28. Vulnerable subjects (e.g. persons kept in detention).&#xD;
&#xD;
         29. Subjects who are study site employees or immediate family members of a study site or&#xD;
             Mabxience employee.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male subjects may be enrolled</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schwabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland Clinical Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Cole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christchurch Clinical Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

